ZanthoSyn Now Available on GNC.com
Inclusion on Key Retail Website Marks Expansion of Cardax/GNC Relationship
HONOLULU--(BUSINESS WIRE)-- Cardax, Inc. (OTCQB:CDXI) announced today that ZanthoSyn, the Company’s premium astaxanthin dietary supplement for inflammatory health and longevity, is now also available on GNC.com, General Nutrition Corporation’s (“GNC”) retail website.
With a worldwide network of more than 9,000 retail locations and two major online channels, GNC is a leading specialty retailer of health, wellness, and performance products. GNC’s online channels represent a significant portion of GNC’s business and offer customers the convenience of online shopping as well as the ability to evaluate and purchase products not available at all retail locations. Online purchases are fulfilled and shipped directly from GNC’s distribution centers to consumers.
“We are very pleased to see this important step unfold in our expanding relationship with GNC,” said Cardax CEO, David G. Watumull. “Their commitment to science based products and consumer education provides a strong foundation for their broad retail reach and aligns perfectly with our business model.”
Cardax devotes substantially all of its efforts to developing and commercializing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.
ZanthoSyn™ is a physician recommended anti-inflammatory supplement for health and longevity that features astaxanthin with optimal absorption and purity. ZanthoSyn is sold online and in Hawaii GNC stores. ZanthoSyn contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to FDA regulations.
Astaxanthin is a clinically studied compound with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, liver health, and mental health.*
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Janice Kam, 1-808-457-1400
Source: Cardax, Inc.
Released June 27, 2017